georgie18
Member Level
Re: georgie18 post# 676239
Wednesday, March 05, 2025 3:58:44 PM
Post#
676296
of 676322
ALLR...$1.09...Trying to Breakout here...🥳
georgie18
Member Level
Re: georgie18 post# 390871
Wednesday, March 05, 2025 1:44:05 PM
Post#
390872
of 390880
ALLR...$1.02...🥳...Psar flipped Bullish...Hit $1.05 Resistance at the 50ma...Lets see if ALLR can Break/Hold $1.05 and Breakout...
georgie18
Member Level
Re: georgie18 post# 676181
Wednesday, March 05, 2025 12:17:51 PM
Post#
676229
of 676236
ALLR...22,000 share buy @ 9782...🥳
georgie18
Member Level
Re: georgie18 post# 390833
Wednesday, March 05, 2025 9:45:01 AM
Post#
390865
of 390870
ALLR...96...Added here...🥳
georgie18
Member Level
Re: georgie18 post# 675910
Tuesday, March 04, 2025 7:48:48 AM
Post#
676027
of 676179
ALLR...92...🥳...Hit $1.01...
georgie18
Member Level
Re: georgie18 post# 390813
Monday, March 03, 2025 9:50:54 AM
Post#
390818
of 390832
ALLR...9455...🥳
georgie18
Member Level
Re: georgie18 post# 675278
Monday, March 03, 2025 8:07:22 AM
Post#
675893
of 675909
ALLR...88...🥳...5 Million dollar board approved repurchase program...announced this morning...
georgie18
Member Level
Re: georgie18 post# 390587
Monday, February 24, 2025 10:52:12 AM
Post#
390694
of 390812
ALLR...79...Added the dip...🥳... https://www.globenewswire.com/news-release/2025/02/24/3031065/0/en/Allarity-Therapeutics-to-Begin-Enrollment-for-New-Phase-2-Protocol-to-Advance-Stenoparib-Toward-FDA-Approval-in-Advanced-Ovarian-Cancer-Patients.html
georgie18
Member Level
Re: georgie18 post# 674892
Friday, February 21, 2025 9:36:04 AM
Post#
675048
of 675277
ALLR...97s clearing here...🥳...Off the .90 range bottom...
georgie18
Member Level
Re: georgie18 post# 389759
Thursday, February 20, 2025 10:06:24 AM
Post#
390508
of 390586
ALLR...Loading .90s...🥳...averaging down...$1.03
georgie18
Member Level
Re: georgie18 post# 673394
Thursday, February 06, 2025 8:08:38 AM
Post#
673498
of 674891
ALLR...$1.23...🥳... https://www.globenewswire.com/news-release/2025/02/06/3021970/0/en/Allarity-Therapeutics-Announces-Expansion-of-Phase-2-Clinical-Trial-to-Accelerate-Development-of-Stenoparib-in-Advanced-Ovarian-Cancer.html
Recent ALLR News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:02:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:22:50 PM
- Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 01:00:48 PM
- Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need • GlobeNewswire Inc. • 02/18/2026 01:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/12/2026 09:18:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:00:35 PM
- Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment • GlobeNewswire Inc. • 02/03/2026 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/29/2026 01:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:49:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:13:58 PM
- Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders • GlobeNewswire Inc. • 12/31/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 02:21:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2025 02:16:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/08/2025 05:15:20 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/03/2025 02:11:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:00:59 PM
- Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2025 08:05:10 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/30/2025 09:17:29 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/25/2025 09:19:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2025 11:58:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2025 09:30:33 PM
- Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months • GlobeNewswire Inc. • 09/22/2025 12:00:28 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
